For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Feburic, Samsca, and More Face First Generics in June Listing, No Xarelto/Eylea AGs
June 16, 2022
- Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
June 16, 2022
- Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
June 16, 2022
- MHLW Proposes KPIs for Creation of Drug Discovery Ecosystem, 3 Other Areas
June 15, 2022
- Japan to Create Expert Panel to Ponder Drug Distribution and Pricing: Kanmin Taiwa
June 15, 2022
- Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
- MSD and Pfizer COVID Pills Add Anaphylaxis in ADR List: Label Update
June 15, 2022
- MHLW Publishes Guidelines for Evaluating SaMDs Used for Behavioral Modification
June 15, 2022
- Lawmakers’ Group Pushes for Legal Steps to Eliminate Drug Lag for Children
June 14, 2022
- LDP’s COVID HQ Compiles Mid-to-Long Term Proposal for Future Pandemics
June 14, 2022
- MSD’s Two-Time PMP Appeals for Lyfnua Rejected: DPO Minutes
June 14, 2022
- Study Finds Lower Fever Rate for Children after COVID Shots
June 13, 2022
- Updated Labels for mRNA Vaccines Flag Risk of Guillain-Barre Syndrome
June 13, 2022
- Japan Mulls Securing AstraZeneca COVID Cocktail If Approved: Minister
June 13, 2022
- Japan Confirms 11 More Probable Cases of Acute Hepatitis in Children
June 13, 2022
- Pharma Wants Govt Purchase for Novel Antimicrobial, Instead of Favorable Pricing
June 10, 2022
- “Re-Do” Pricing Based on New Assumption Rather than Simple Cuts, DPP Lawmaker Says on Re-Pricing Rules
June 10, 2022
- MHLW Council OKs Public Knowledge-Based Applications for 3 Drugs Including Acetaminophen
June 9, 2022
- 60% in Japan Get Three COVID Shots, Nearly 90% for Older Adults: Govt
June 9, 2022
- Edurant Label Revised for Combined Use with Vocabria
June 8, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…